CTOs on the Move

OmniSYS

www.omnisys.com

 
OmniSYS is a technology company with 25+ years of experience working with pharmacies, payers, providers and pharmaceutical manufacturers. We leverage this unique market insight along with our pharmacy workflow expertise to deliver valuable solutions that help pharmacies thrive in the changing pharmacy landscape. Our solutions help pharmacies engage patients, grow clinical services and improve financial performance. OmniSYS currently serves over 25,000 pharmacies, connects to hundreds of payers and touches millions of patient lives.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.omnisys.com
  • 15950 Dallas Parkway Suite 350
    Dallas, TX USA 75248
  • Phone: 214.459.2574

Executives

Name Title Contact Details

Similar Companies

Carolina Centers for Medical Excellence

Carolina Centers for Medical Excellence is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Health Enterprises Of Iowa

Health Enterprises Of Iowa is a Cedar Rapids, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jackson Park Christian Home

Jackson Park Christian Home is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

International Society for Medical Publication

International Society for Medical Publication is a Briarcliff Manor, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.